Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On

MADRID — Should patients with resectable non–small cell lung cancer (NSCLC) receive adjuvant therapy, neoadjuvant therapy, or both experts asked during a special session at the European Society for Medical Oncology (ESMO) Congress 2023 on October 21. Though immunotherapy is beneficial in resectable NSCLC, “we actually don’t know how much of the effect [is due to] the adjuvant and how […]
» Read more